Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

3836 - Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Wim Meer

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

W.V.D. Meer1, E.A. Basak2, D.P. Hurkmans1, M.W.J. Schreurs3, E. Oomen-de Hoop1, A.A.M. Van der Veldt4, S. Bins5, A. Joosse6, S.L. Koolen7, R. Debets8, R.P. Peeters9, J.G. Aerts10, R.H. Mathijssen11, M. Medici12

Author affiliations

  • 1 Medical Oncology, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 2 Medical Oncology, Erasmus University Medical Center, 3015 GD - Rotterdam/NL
  • 3 Immunology, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 4 Medical Oncology And, Radiology And Nuclear Medicine, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 5 Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075EA - Rotterdam/NL
  • 6 Medical Oncology, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 7 Medical Oncology And, Hospital Pharmacy, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 8 Medical Oncology, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 9 Internal Medicine And Erasmus Mc Academic Center For Thyroid Diseases, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 10 Pulmonology, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 11 Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA - Rotterdam/NL
  • 12 Internal Medicine And Erasmus Mc Academic Center For Thyroid Diseases, Erasmus University Medical Center, 3015 GD - Rotterdam/NL
More

Resources

Abstract 3836

Background

Thyroid dysfunction is one of the most common adverse effects during anti-PD-1 therapy, and alongside elevated anti-thyroid antibodies (ATAb) it is correlated with overall (OS) and progression free survival (PFS). The objective and novelty of our study was the simultaneous investigation of thyroid dysfunction and ATAbs on survival.

Methods

We included 168 patients with non-small cell lung carcinoma (n = 93), renal cell carcinoma (n = 12), and advanced and metastatic melanoma (n = 63) treated with nivolumab or pembrolizumab. TSH and fT4 serum levels were measured prior to each anti-PD-1 infusion and ATAb titers in sera, i.e. anti-TPO and anti-Tg (cut-off: 3.05 IU/ml and 22.35 IU/ml, respectively; based on median value at baseline), at baseline, and after 2 months of treatment. Thyroid dysfunction was based on TSH and fT4 and classified as subclinical or overt. Tumor progression was classified according to RECIST v1.1 and was monitored until progression, death or withdrawal of the study. Cox regression was used with correction for tumor type.

Results

Patients who acquired overt thyroid toxicity during anti-PD-1 treatment had significantly higher OS (HR = 0.17 [95% CI: 0.04-0.74]; p = 0.018) and PFS (HR = 0.38 [0.15-0.98]; p = 0.05) than patients without thyroid toxicity with one-year OS rates of 95% vs 64% and one-year PFS rates of 65% vs 33%. Moreover, patients with positive ATAb status during treatment had higher OS (HR = 0.39 [0.21-0.72]; p = 0.003) and PFS (HR = 0.52 [0.33-0.81]; p = 0.004) than patients with negative ATAb status with one-year OS rates of 83% vs 49% and PFS rates of 54% vs 20%, respectively. For 84% of patients the ATAb status at baseline was the same as during treatment. Patients with persistent positive ATAb status (48%) had higher OS (HR = 0.41 [0.19-0.89], p = 0.03) and PFS (HR = 0.54 [0.31-0.95], p = 0.03) compared to patients with persistent negative ATAb status (36%).

Conclusions

Acquired overt thyroid toxicity and positive ATAb status during anti-PD-1 treatment are associated with improved PFS and OS. Moreover, our results indicate that ATAb status at baseline is of clinical relevance for PFS and OS. If validated, these parameters may serve as a novel positive predictive markers.

Clinical trial identification

Dutch trial register: MULTOMAB, NL6828.

Editorial acknowledgement

Legal entity responsible for the study

Erasmus Medical Center.

Funding

Erasmus Medical Center.

Disclosure

A.A.M. Van der Veldt: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Merck Sharp & Dohme. R.H. Mathijssen: Research grant / Funding (institution), Travel / Accommodation / Expenses: Astellas; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Boekringer; Research grant / Funding (institution): Cristal Therapeutics; Honoraria (self), Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pamgene; Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Sanofi; Honoraria (self): Servier. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings